MX2012001449A - Inhibidores de cinasas c-jun-n-terminales (jnk). - Google Patents
Inhibidores de cinasas c-jun-n-terminales (jnk).Info
- Publication number
- MX2012001449A MX2012001449A MX2012001449A MX2012001449A MX2012001449A MX 2012001449 A MX2012001449 A MX 2012001449A MX 2012001449 A MX2012001449 A MX 2012001449A MX 2012001449 A MX2012001449 A MX 2012001449A MX 2012001449 A MX2012001449 A MX 2012001449A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- jnk
- inhibitors
- compounds
- disclosed
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000012825 JNK inhibitor Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23252209P | 2009-08-10 | 2009-08-10 | |
| PCT/EP2010/061476 WO2011018417A1 (en) | 2009-08-10 | 2010-08-06 | Inhibitors of jnk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012001449A true MX2012001449A (es) | 2012-03-26 |
Family
ID=42710723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012001449A MX2012001449A (es) | 2009-08-10 | 2010-08-06 | Inhibidores de cinasas c-jun-n-terminales (jnk). |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8536172B2 (enExample) |
| EP (1) | EP2464640A1 (enExample) |
| JP (1) | JP5784604B2 (enExample) |
| KR (1) | KR101506318B1 (enExample) |
| CN (1) | CN102471319B (enExample) |
| AR (1) | AR077820A1 (enExample) |
| AU (1) | AU2010283769B2 (enExample) |
| BR (1) | BR112012003059A2 (enExample) |
| CA (1) | CA2768749A1 (enExample) |
| IL (1) | IL217756A0 (enExample) |
| IN (1) | IN2012DN01231A (enExample) |
| MX (1) | MX2012001449A (enExample) |
| SG (1) | SG178321A1 (enExample) |
| TW (1) | TW201109336A (enExample) |
| WO (1) | WO2011018417A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012030814A2 (pt) * | 2010-06-04 | 2019-09-24 | Hoffmann La Roche | inibidores de jnk |
| NZ705040A (en) * | 2012-07-20 | 2017-07-28 | Cleave Biosciences Inc | Fused pyrimidines as inhibitors of p97 complex |
| EA201501080A1 (ru) * | 2013-06-26 | 2016-07-29 | Ксижен Инфлемейшн Лтд. | Новое применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения различных заболеваний |
| MX358346B (es) * | 2014-04-04 | 2018-08-15 | Syros Pharmaceuticals Inc | Inhibidores de la quinasa dependiente de ciclina 7 (cdk7). |
| ES2985135T3 (es) | 2014-12-18 | 2024-11-04 | Harvard College | Procedimientos para generar células ß derivadas de células madre y usos de las mismas |
| JP2018507900A (ja) * | 2015-03-13 | 2018-03-22 | アッヴィ・インコーポレイテッド | （インダゾール−４−イル）ヘキサヒドロピロロピロロン及び使用方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101177729B1 (ko) * | 2006-09-08 | 2012-09-07 | 에프. 호프만-라 로슈 아게 | 벤조트리아졸 키나아제 조절제 |
| BRPI0720003A2 (pt) * | 2006-12-08 | 2018-09-18 | Hoffmann La Roche | pirimidinas substituídas e seu uso como moduladores de jnk |
-
2010
- 2010-08-06 IN IN1231DEN2012 patent/IN2012DN01231A/en unknown
- 2010-08-06 BR BR112012003059A patent/BR112012003059A2/pt not_active IP Right Cessation
- 2010-08-06 AU AU2010283769A patent/AU2010283769B2/en not_active Ceased
- 2010-08-06 WO PCT/EP2010/061476 patent/WO2011018417A1/en not_active Ceased
- 2010-08-06 SG SG2012008819A patent/SG178321A1/en unknown
- 2010-08-06 CN CN201080035300.3A patent/CN102471319B/zh not_active Expired - Fee Related
- 2010-08-06 CA CA2768749A patent/CA2768749A1/en not_active Abandoned
- 2010-08-06 KR KR1020127006275A patent/KR101506318B1/ko not_active Expired - Fee Related
- 2010-08-06 JP JP2012524207A patent/JP5784604B2/ja not_active Expired - Fee Related
- 2010-08-06 MX MX2012001449A patent/MX2012001449A/es active IP Right Grant
- 2010-08-06 EP EP10739948A patent/EP2464640A1/en not_active Withdrawn
- 2010-08-09 TW TW099126517A patent/TW201109336A/zh unknown
- 2010-08-09 AR ARP100102908A patent/AR077820A1/es unknown
- 2010-08-09 US US12/852,540 patent/US8536172B2/en not_active Expired - Fee Related
-
2012
- 2012-01-26 IL IL217756A patent/IL217756A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010283769A1 (en) | 2012-02-09 |
| AR077820A1 (es) | 2011-09-28 |
| WO2011018417A1 (en) | 2011-02-17 |
| EP2464640A1 (en) | 2012-06-20 |
| US8536172B2 (en) | 2013-09-17 |
| KR101506318B1 (ko) | 2015-03-26 |
| BR112012003059A2 (pt) | 2016-08-02 |
| SG178321A1 (en) | 2012-03-29 |
| US20110034470A1 (en) | 2011-02-10 |
| CA2768749A1 (en) | 2011-02-17 |
| IN2012DN01231A (enExample) | 2015-05-15 |
| IL217756A0 (en) | 2012-03-29 |
| JP5784604B2 (ja) | 2015-09-24 |
| KR20120055645A (ko) | 2012-05-31 |
| TW201109336A (en) | 2011-03-16 |
| JP2013501746A (ja) | 2013-01-17 |
| AU2010283769B2 (en) | 2015-09-17 |
| CN102471319B (zh) | 2014-06-18 |
| CN102471319A (zh) | 2012-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX348024B (es) | Compuestos de adamantilo. | |
| PH12012502212A1 (en) | Nitrogen heterocyclic compounds usefulas pde10 inhibitors | |
| MX2009013353A (es) | Compuestos activadores de telomerasa y metodos para su uso. | |
| MX2009006195A (es) | Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso. | |
| MX2011007750A (es) | Composiciones y metodos para inhibicion de la ruta jak. | |
| TW200744586A (en) | Therapeutic compounds | |
| MX2009009590A (es) | Aminopirimidinas utiles como inhibidores de proteinas cinasas. | |
| TN2010000028A1 (en) | Compounds and methods for modulating fxr | |
| TN2011000339A1 (en) | Poly (adp-ribose) polymerase (parp) inhibitors | |
| WO2012016186A8 (en) | Macrocyclic kinase inhibitors and uses thereof | |
| MX347917B (es) | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. | |
| IN2012DN03883A (enExample) | ||
| MX367623B (es) | 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3. | |
| MY153057A (en) | Tryclic compounds,compositions and methods | |
| MX2020009397A (es) | Composiciones y metodos para inhibicion de la via jak. | |
| MX337190B (es) | Nuevas bencensulfonamidas como bloqueadores del canal de calcio. | |
| MX2012001134A (es) | Composiciones y metodos para inhibicion de la via jak. | |
| MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
| IN2012DN03846A (enExample) | ||
| MX2014000374A (es) | Compuesto de aminometil quinolona. | |
| WO2006093547A3 (en) | Novel lipoxygenase inhibitors | |
| IN2012DN01231A (enExample) | ||
| JO2682B1 (en) | Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof | |
| MY152040A (en) | Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments | |
| MX342119B (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |